| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| pmid: | ||||
| Werbovetz KA et al. | Purification, characterization, and drug susceptibility of tubulin from Leishmania. | 1999 | Mol. Biochem. Parasitol. | pmid:10029309 |
| Suchocki JA and Sneden AT | Characterization of decomposition products of maytansine. | 1987 | J Pharm Sci | pmid:11002812 |
| Havens CG et al. | Cellular effects of leishmanial tubulin inhibitors on L. donovani. | 2000 | Mol. Biochem. Parasitol. | pmid:11071278 |
| Monneret C and Florent JC | [Targeting of antitumor drugs with monoclonal antibodies]. | 2000 | Bull Cancer | pmid:11125291 |
| Smith S | Technology evaluation: C242-DM1, ImmunoGen Inc. | 2001 | Curr. Opin. Mol. Ther. | pmid:11338934 |
| Carroll BJ et al. | Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. | 2002 | J. Am. Chem. Soc. | pmid:11960423 |
| Ross S et al. | Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. | 2002 | Cancer Res. | pmid:11980648 |
| Moss SJ et al. | Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. | 2002 | J. Am. Chem. Soc. | pmid:12047169 |
| Yu TW et al. | The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. | 2002 | Proc. Natl. Acad. Sci. U.S.A. | pmid:12060743 |
| Ranson M and Sliwkowski MX | Perspectives on anti-HER monoclonal antibodies. | 2002 | Oncology | pmid:12422051 |
| Tolcher AW et al. | Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. | 2003 | J. Clin. Oncol. | pmid:12525512 |
| Pullen CB et al. | Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. | 2003 | Phytochemistry | pmid:12620351 |
| Hamel E | Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. | 1992 | Pharmacol. Ther. | pmid:1287674 |
| Cruz-Monserrate Z et al. | Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. | 2003 | Eur. J. Biochem. | pmid:12950266 |
| Sieber SM et al. | Pharmacology of antitumor agents from higher plants. | 1976 | Cancer Treat Rep | pmid:136296 |
| Yue XF et al. | Cytotoxic activity of trewiasine in 4 human cancer cell lines and 5 murine tumors. | 1992 | Zhongguo Yao Li Xue Bao | pmid:1442109 |
| Osieka R et al. | Chemotherapy of human colon cancer xenografts in athymic nude mice. | 1977 | Cancer | pmid:144557 |
| Spiteller P et al. | The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. | 2003 | J. Am. Chem. Soc. | pmid:14624546 |
| Xie H et al. | Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. | 2004 | J. Pharmacol. Exp. Ther. | pmid:14634038 |
| Cassady JM et al. | Recent developments in the maytansinoid antitumor agents. | 2004 | Chem. Pharm. Bull. | pmid:14709862 |
| Okamoto K et al. | Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody. | 1992 | Jpn. J. Cancer Res. | pmid:1517150 |
| Tassone P et al. | In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. | 2004 | Cancer Res. | pmid:15231675 |
| Helft PR et al. | A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. | 2004 | Clin. Cancer Res. | pmid:15240523 |
| Tassone P et al. | Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. | 2004 | Blood | pmid:15292058 |
| Lu C et al. | A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum. | 2004 | J. Antibiot. | pmid:15303496 |
| Nakao H et al. | Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells. | 2004 | Biol. Pharm. Bull. | pmid:15305028 |
| Li Y et al. | Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1530630 |
| Henry MD et al. | A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. | 2004 | Cancer Res. | pmid:15520207 |
| Liu Z et al. | An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. | 2004 | J Pharm Biomed Anal | pmid:15533675 |
| Carter SK | New drugs under clinical evaluation in the United States. | 1978 | Cancer Chemother. Pharmacol. | pmid:155503 |
| Smith SV | Technology evaluation: cantuzumab mertansine, ImmunoGen. | 2004 | Curr. Opin. Mol. Ther. | pmid:15663331 |
| Liu Z et al. | Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. | 2005 | J Mass Spectrom | pmid:15674857 |
| Lu SX et al. | Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. | 2005 | J Pharm Sci | pmid:15729708 |
| Hanka LJ and Barnett MS | Microbiological assays and bioautography of maytansine and its homologues. | 1974 | Antimicrob. Agents Chemother. | pmid:15825322 |
| Fleming MS et al. | A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. | 2005 | Anal. Biochem. | pmid:15840500 |
| Lazar AC et al. | Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. | 2005 | Rapid Commun. Mass Spectrom. | pmid:15945030 |
| Wang L et al. | Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. | 2005 | Protein Sci. | pmid:16081651 |
| Smith SV | Technology evaluation: huN901-DM1, ImmunoGen. | 2005 | Curr. Opin. Mol. Ther. | pmid:16121706 |
| Frenzel T et al. | Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. | 2006 | Org. Lett. | pmid:16381586 |
| Floss HG | Combinatorial biosynthesis--potential and problems. | 2006 | J. Biotechnol. | pmid:16414140 |
| Kovtun YV et al. | Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. | 2006 | Cancer Res. | pmid:16540673 |
| Erickson HK et al. | Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. | 2006 | Cancer Res. | pmid:16618769 |
| Dymowski W and Furmanowa M | [Investigating cytostatic substances in tissue of plants Maytenus Molina in in-vitro cultures. II. chromatographic test of extracts from callus of Maytenus wallichiana R. et B]. | 1990 | Acta Pol Pharm | pmid:1669332 |
| Widdison WC et al. | Semisynthetic maytansine analogues for the targeted treatment of cancer. | 2006 | J. Med. Chem. | pmid:16821799 |
| Kubota T et al. | Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. | 2006 | Chembiochem | pmid:16927319 |
| Tijink BM et al. | A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. | 2006 | Clin. Cancer Res. | pmid:17062682 |
| Wenzel SC et al. | On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. | 2006 | J. Am. Chem. Soc. | pmid:17076505 |
| Tan GT et al. | Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991 Jan-Feb | J. Nat. Prod. | pmid:1710653 |
| Chari RV et al. | Immunoconjugates containing novel maytansinoids: promising anticancer drugs. | 1992 | Cancer Res. | pmid:1727373 |